Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026

Otsuka presented additional Phase 3b analyses of centanafadine in adults with ADHD and comorbid anxiety disorders at Psych Congress 2026, expanding on positive topline results disclosed in June. The supplied excerpt characterizes the new analysis as the most comprehensive view of the program to date but provides no efficacy, safety, or statistical data; the update is therefore incrementally positive for the drug's development outlook.

Analysis

The investable issue is not clinical signal direction but whether centanafadine can earn a differentiated place in the adult ADHD algorithm. A non-stimulant option with credible anxiety-comorbidity utility could take share disproportionately from generic atomoxetine and branded non-stimulants rather than from stimulants, where efficacy familiarity and payer behavior remain entrenched. For Otsuka Holdings (4578 JP; OTC proxy OTSKF), even a successful launch is unlikely to alter near-term consolidated estimates without pricing, label language, and launch-timing disclosure; this is a pipeline-optionality catalyst, not yet an earnings catalyst.

The most exposed listed competitor is Supernus (SUPN), whose Qelbree franchise depends on continued non-stimulant ADHD uptake and premium reimbursement. The relevant read-through is whether centanafadine demonstrates a cleaner anxiety, sleep, cardiovascular, or discontinuation profile—not merely statistical efficacy—because those attributes determine formulary positioning and persistence. Over the next 1-3 months, investor attention should focus on full safety tables, effect size versus placebo, functional endpoints, and any indication that Otsuka will pursue a differentiated comorbid-anxiety label claim; absent these, the presentation has limited power to change market share assumptions.

Consensus may overvalue the apparent addressable market: adult ADHD treatment is large, but generic substitution, prior authorization, and stimulant-first prescribing can materially delay revenue conversion. Conversely, a meaningful reduction in anxiety-related treatment discontinuation could expand the treated population rather than simply displace existing therapies, making the commercial upside underappreciated over 6-18 months. The thesis is falsified by safety findings that narrow the tolerability advantage, a non-differentiated label, or payer controls that place the product behind generic atomoxetine and Qelbree.

Key Decisions for Investors

• No immediate directional position in 4578 JP/OTSKF: wait for regulatory status, label strategy, pricing, and management revenue guidance. Treat the program as immaterial to current-year earnings until a launch timetable and peak-sales framework are disclosed.
• Place SUPN on a 1-3 month competitive-risk watch: consider a tactical short only if detailed centanafadine data show a clinically credible anxiety/tolerability advantage and Otsuka signals broad commercial launch. Cover if formulary access is uncertain or centanafadine lacks differentiated labeling, since Qelbree’s incumbent commercial infrastructure can blunt early share loss.
• For healthcare portfolios, monitor adult-ADHD prescription trends and payer policy rather than conference headlines. An acceleration in non-stimulant new-to-brand prescriptions following approval would be the first independently verifiable signal that supports reallocating from SUPN toward Otsuka exposure.
• Reassess after full data publication: a discontinuation-rate advantage of several percentage points, favorable cardiovascular findings, and functional improvement would justify assigning meaningful probability to incremental category growth; efficacy-only data would not.